SCHEMBL18308997

SCHEMBL18308997

CN[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
XPNPEP1 Q9NQW7 1/20 0.37
ACE2 Q9BYF1 2/20 0.36
ACE P12821 5/20 0.35
REN P00797 4/20 0.35
KDM4E B2RXH2 1/20 0.35
F2 P00734 1/20 0.35
LMNA P02545 1/20 0.35
LTA4H P09960 1/20 0.35
MAPT P10636 1/20 0.35
PEPD P12955 1/20 0.35
ALOX15 P16050 1/20 0.35
PTGS1 P23219 1/20 0.35
HTR2A P28223 1/20 0.35
PTGS2 P35354 1/20 0.35
HRH1 P35367 1/20 0.35
THPO P40225 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12841626 0.85 DPP4 (0.37) DPP4DPP8DPP9DPP7ACE2
SCHEMBL25963840 0.85 DPP4 (0.39) DPP4DPP8DPP9DPP7XPNPEP1
SCHEMBL16330589 0.82 DPP4 (0.44) DPP4DPP8DPP9DPP7XPNPEP1
SCHEMBL19372640 0.81 ACE (0.47) DPP4DPP8DPP9DPP7ACE2
SCHEMBL16300495 0.80 ACE (0.43) DPP4DPP8DPP9DPP7ACE2
SCHEMBL24448586 0.79 DPP4 (0.63) DPP4DPP8DPP9DPP7XPNPEP1
SCHEMBL17760537 0.79 DPP4 (0.63) DPP4DPP8DPP9DPP7XPNPEP1
SCHEMBL12001763 0.78 ACE (0.41) DPP4DPP8DPP9DPP7ACE2
SCHEMBL13508877 0.77 ALDH1A1 (0.49) DPP4DPP8DPP9DPP7ACE2
SCHEMBL22525831 0.75 DPP4 (0.39) DPP4DPP8DPP9DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023141856-A1 CD3-TARGETING MULTISPECIFIC ANTIBODY AND USE THEREOF 岩唐生物科技(杭州)有限责任公司 2023-08-03 WO disclosed
US-20160361378-A1 MULTIVALENT/MULTIFUNCTIONAL LIGANDS WITH AGONIST ACTIVITIES AT OPIOID RECEPTORS AND ANTAGONIST ACTIVITIES AT NK1 RECEPTOR FOR RELIEF OF PAIN THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361378-A1 MULTIVALENT/MULTIFUNCTIONAL LIGANDS WITH AGONIST ACTIVITIES AT OPIOID RECEPTORS AND ANTAGONIST ACTIVITIES AT NK1 RECEPTOR FOR RELIEF OF PAIN OPRK1, OPRL1, OPRM1 DPP4 2034/4885DPP8 1322/4885DPP9 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.